Semaglutide WADA status

Athletes who are prescribed semaglutide for weight management or type-2 diabetes often ask the same question before competition: does taking it require a Therapeutic Use Exemption, or is it on the prohibited list? The short answer is no, it is not prohibited^[1]. The longer answer requires understanding how the World Anti-Doping Agency (WADA) evaluates substances, and what its current monitoring position on GLP-1 receptor agonists actually means.

This article explains the current WADA status of semaglutide, the monitoring program context, and what athletes should know before relying on any specific source for a competition ruling. It does not constitute medical or legal advice. Any decision about medication use in a competitive context belongs with a clinician and, where relevant, a sports pharmacist or anti-doping advisor.

Current WADA status: not prohibited

Semaglutide belongs to the GLP-1 receptor agonist class. As of the date of this article, GLP-1 receptor agonists are not listed on the WADA Prohibited List^[1]. Athletes do not need a Therapeutic Use Exemption (TUE) to use them. This applies to all three branded semaglutide presentations: Ozempic (subcutaneous injection for type-2 diabetes, authorised by the EMA in February 2018^[2]), Wegovy (subcutaneous injection for weight management, authorised by the EMA in January 2022^[3]), and Rybelsus (oral tablet for type-2 diabetes).

The WADA Prohibited List is updated annually and takes effect on 1 January each year. Substances are added when they meet at least two of three criteria: the potential to enhance performance, an actual or potential health risk, or violation of the spirit of sport. Semaglutide meets none of these criteria in the judgment of the anti-doping bodies that have assessed it.

What WADA monitoring means

Although semaglutide is not prohibited, WADA is actively monitoring and evaluating the use of GLP-1 agonists by athletes to determine whether they should be prohibited in the future^[1]. The WADA Monitoring Program is a formal process for gathering prevalence data on substances that are not yet banned but where the agency wants to assess usage patterns before making a prohibition decision.

Being on the monitoring program is not the same as being prohibited. Athletes whose samples are tested are not sanctioned for substances in the monitoring program. The distinction matters: a substance can move from monitored to prohibited in a future list year if the evidence warrants it. It can equally remain permitted indefinitely if the evidence does not.

The rationale for monitoring GLP-1 agonists is straightforward. These drugs produce substantial reductions in body weight, and body composition is a meaningful variable in weight-class sports and in endurance disciplines where the power-to-weight ratio determines performance. The question WADA is working through is whether the weight change constitutes a prohibited performance-enhancing mechanism.

The named substance versus catch-all distinction

The WADA Prohibited List uses two mechanisms to cover substances. First, it names specific substances explicitly. Second, it includes class descriptions and catch-all language that can extend to substances that are pharmacologically related to named agents but not individually listed. This catch-all structure matters for athletes because a substance does not need to appear by name to be considered prohibited if it belongs to a prohibited class.

GLP-1 receptor agonists are not currently captured by any catch-all class on the prohibited list^[1]. The hormone and metabolic modulator categories that exist on the list (covering agents like insulin, GH secretagogues, and SARMs) do not extend to GLP-1 agonists as currently written. That is the position as of this article's editorial date. Athletes competing in sports governed by WADA-compliant anti-doping codes should verify the current list at GlobalDRO.com, the tool USADA and other national anti-doping organisations recommend for per-substance, per-sport status checks.

Practical checklist for competing athletes

Four steps worth taking before any competition where anti-doping testing applies:

First, verify the current status. The prohibited list changes annually. An article published in a previous year may not reflect the current list. Use GlobalDRO.com with your sport and country of purchase selected. This is the source USADA formally recommends for per-substance status checks.

Second, confirm the branded product. GlobalDRO searches by brand name, not just active ingredient. Ozempic, Wegovy, and Rybelsus are the authorised branded products. Compounded or unlicensed semaglutide versions carry an additional layer of uncertainty: the active ingredient content of compounded versions may not match the label, and some compounded preparations have contained undisclosed additives. USADA has documented cases where unlicensed online products labelled as GLP-1 agonists contained incorrect ingredients or dangerous dosing errors.

Third, check your sport's governing body rules. Some sports federations operate their own prohibited lists in addition to, or instead of, the WADA list. The status of a substance under the WADA code does not automatically determine its status under every federation's rules. For semaglutide this is unlikely to differ, but the check is standard practice for any prescription medicine.

Fourth, tell your prescribing clinician you compete. A clinician who knows you are subject to anti-doping testing can flag any new prescription against the current prohibited list before you start the medication.

Performance questions and the spirit of sport debate

Some sports science commentators have raised the question of whether semaglutide's weight-loss effect constitutes an indirect performance advantage in weight-class sports: a fighter who uses semaglutide to compete at a lower weight class achieves a structural advantage that the drug, not training, produced. The same argument has been applied to endurance sport, where power-to-weight ratio is the primary performance variable.

WADA's monitoring programme is partly a response to this debate. The agency has not concluded that the effect is prohibited, but it is gathering data. The outcome of that evaluation, whatever it is, will shape the next revision of the prohibited list. Until then, semaglutide remains permitted^[1].

Athletes, coaches and support staff who want to engage with that debate in good faith should be aware that the argument is live. The anti-doping position today is different from what it might be in two or three list years. Monitoring the WADA Annual Prohibited List releases each September (for the following January) is the practical way to stay current.

Disclaimer

This article is for educational and journalistic purposes only. It does not constitute medical, legal, or anti-doping advice. Semaglutide is a prescription-only medicine across every jurisdiction PeptideMethods covers. Competitive athletes should verify the current status of any medication with their national anti-doping organisation, their sport's governing body, and a clinician before use. The country-by-country regulatory status of semaglutide is on the semaglutide peptide page.